Alto Neuroscience, Inc.
ANRO- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001999480
No open-market purchases or sales by Alto Neuroscience, Inc. insiders were filed in the last 90 days; 114 institutions reported holding it in 13F filings for Q2 2026, worth $777.6M in total; no superinvestor holds it.
Holders of 5% or more of ANRO
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Alto Neuroscience, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Commodore Capital LP | 13G | 9.80%3.19M shares | New | Oct 27, 20251 filing | Oct 27, 2025 | SEC |
| Perceptive Advisors LLC | 13G | 7.30%1.99M shares | New | Oct 10, 20251 filing | Oct 10, 2025 | SEC |
| Point72 Asset Management, L.P. | 13G/A | 7.00%1.91M shares | −1.80 ppfrom 8.80% | Feb 14, 20252 filings | May 15, 2025 | SEC |
| Armistice Capital, LLC | 13G/A | 6.00%1.62M shares | +0.09 ppfrom 5.91% | May 15, 20252 filings | Aug 14, 2025 | SEC |
| K2 HealthVentures Equity Trust LLC | 13G | 5.60%1.62M shares | New | May 15, 20251 filing | May 15, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on Alto Neuroscience, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Oct 27, 20254:02 PM ET | Commodore Capital LPand 3 others | 13G | 9.80%3.19M shares | New | Oct 20, 2025 | SEC |
| Oct 10, 202512:50 PM ET | Perceptive Advisors LLCand 2 others | 13G | 7.30%1.99M shares | New | Oct 3, 2025 | SEC |
| Aug 14, 20259:36 PM ET | Armistice Capital, LLCand 1 other | 13G/A | 6.00%1.62M shares | +0.09 ppfrom 5.91% | Jun 30, 2025 | SEC |
| Jul 16, 20257:02 PM ET | BlackRock, Inc. | 13G/A | 2.10%561.4K shares | –Below 5% | Jun 30, 2025 | SEC |
| May 15, 20254:26 PM ET | Point72 Asset Management, L.P.and 5 others | 13G/A | 7.00%1.91M shares | −1.80 ppfrom 8.80% | Mar 31, 2025 | SEC |
| May 15, 20253:19 PM ET | K2 HealthVentures Equity Trust LLCand 2 others | 13G | 5.60%1.62M shares | New | Jan 13, 2025 | SEC |
| May 15, 20253:05 PM ET | Armistice Capital, LLCand 1 other | 13G | 5.91%1.60M shares | New | Mar 31, 2025 | SEC |
| Feb 14, 20256:26 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 0.00%0 shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 20254:05 PM ET | Point72 Asset Management, L.P.and 5 others | 13G/A | 8.80%2.36M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 20259:16 AM ET | FMR LLCand 1 other | 13G/A | 4.70%1.27M shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Alto Neuroscience, Inc. shares.
No Form 144 notices for Alto Neuroscience, Inc. are on file.